Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2010 - 2025)

Fennec Pharmaceuticals' Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $70.6 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 56.97% year-over-year to $70.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $211.1 million (down 10.64% YoY) and the FY2025 annual result came in at $70.6 million, up 56.97% from the prior year.
• Liabilities and Shareholders Equity was $70.6 million for Q4 2025 at Fennec Pharmaceuticals, up from $49.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $70.6 million in Q4 2025 and bottomed at $15.6 million in Q2 2022.
• A 5-year average of $36.6 million and a median of $28.0 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 44.63% — and 2024, when it surged 224.95%.
• Fennec Pharmaceuticals' Liabilities and Shareholders Equity stood at $22.4 million in 2021, then increased by 20.19% to $26.9 million in 2022, then retreated by 0.28% to $26.9 million in 2023, then jumped by 67.31% to $44.9 million in 2024, then soared by 56.97% to $70.6 million in 2025.
• Business Quant data shows FENC's Liabilities and Shareholders Equity at $70.6 million in Q4 2025, $49.3 million in Q3 2025, and $44.9 million in Q2 2025.